Alfuzosin for the management of benign prostate hyperplasia

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 11, 2003, Pages 2057-2063

  Weiner, David M ^a   Lowe, Franklin C ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

1 antagonist; Alfuzosin; Benign prostate hyperplasia

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PLACEBO; PRAZOSIN; QUINAZOLINE DERIVATIVE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; MALE; MULTIPLE DRUG DOSE; ORTHOSTATIC HYPOTENSION; POSTMARKETING SURVEILLANCE; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; SUSTAINED RELEASE FORMULATION; SYNCOPE; TABLET FORMULATION; TACHYCARDIA; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG APPROVAL; HUMANS; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTATIC HYPERPLASIA; QUINAZOLINES;

EID: 0242407422     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.11.2057     Document Type: Review

References (37)

1. BERRY SJ, COFFEY DS, WALSH PC, EWING LL: The development of human benign prostatic hyperplasia with age. J. Urol. (1984) 132:474-479.
2. BUZELIN JM, ROTH S, GEFFRIAUD-RICOUARD C, DELAUCHE-CAVALLIER MC: Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. ALEGBI Study Group. Eur. Urol. (1997b) 31:190-198.
3. JARDIN A, BENSADOWN H, DELAUCHE-CAVALLIER MC, ATTALLI P: Alfuzosin for the treatment of benign prostatic hyperplasia. The BPH-ALF Group. Lancet (1991) 337:1457-1460.
4. TEILLAC P, DELAUCHE-CAVALLIER MC, ATTALI P: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. The DUALF Group. Br. J. Urol. (1992) 70:58-64.
5. LUKAS B, BLONDIN P, MCCARTHY C, DUBOYS B, GRIPPON P, LASSALE C: Safety profile of 3-month therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur. Urol. (1996) 29:29-35.
6. AHTOY P, CHRETIEN P, DUPAIN T, RAUCH C, ROUCHOUSE A, DELFOLIE A: Alfuzosin, an alpha-1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. Int. J. Clin. Pharm. Ther. (2002) 40(7):289-294.
7. RAUCH-DESANTI C, FRAISSE J, DUBRUC C, MAHRAOUI L, THENOT JP: Pharmacokinetics and metabolic profiles of alfuzosin. In: Benign prostatic hyperplasia - the place of alfuzosin. Debruyne FMJ, Jardin A, Roehrborn CJ, Langer SZ (Eds), Adis International. (1998):63-73.
8. CAINE M, RAZ S, ZIEGLER M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br. J. Urol. (1975) 27:193-202.
9. DJAVAN B, MARBERGER M: A meta-analysis of the efficacy and tolerability of alpha-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. (1999) 36:1-13.
10. BASAR MM, ATAN A, OZERGIN O, YILDIZ M: The efficacy of alfuzosin treatment in patients with prostatism. Int. Urol. Nephrol. (2001) 33:493-497,
11. LEFEVRE-BORG F, LECHAIRE J, O'CONNOR S: In vivo uroselectivity of alfuzosin compared to prazosin and terazosin. Br. J. Pharmacol. (1992) 106:84.
12. ROUQUIERY, CLAUSTRE Y, BENAVIDES J: Alpha-1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur. J. Pharmacol (1994) 261:59-64.
13. BUZELIN JM, DELAUCHE-CAVALLIER MC, ROTH S, GEFFRAIUD-RICOUARD C, SANTONI JP: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1997) 79:898-906.
14. LUKACS B, MCCARTHY C, GRANGE JC: Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with alpha-1 adrenergic blocker alfuzosin. The QOL BPH Study Group In General Practice. Eur. Urol. (1993) 24(Suppl. 1):34-47.
15. PERRIGOT M, DELAUCHE-CAVALLIER MC, AMARENCO G, GEFFRIAUD C, STALLA-BOURDILLON A, COSTA P: Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder disease. The Dorali Study Group. Neurourol. Urodynam. (1996) 15:119-131.
16. LEPOR H: Non operative management of benign prostatic hypertrophy. J. Urol. (1989) 141:1283-1289.
17. BUZELIN JM, HERBERT M, BLONDIN P: Alpha blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The Prazalf Group. Br. J. Urol. (1993) 72:922-927.
18. STEPHENSON TP, JENSEN RD AND THE PRANALF GROUP: A placebo-controlled study of the efficacy and tolerability of alfuzosin and prazosin for the treatment of benign prostatic hypertrophy (BPH). Proceedings XIth Congress of the European Association of Urology, Berlin Germany. (1994) 25(Abstract 48).
19. LOWE FC: Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology (1994) 44:46-51.
20. JANKNEGT RA, CHAPPLE CR: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. The Doxazosin Study Groups. Eur. Urol. (1993) 24:319-326.
21. ABRAMS P, SCHULMAN CC, VAAGE S: Tamsulosin. A selective alpha-1c adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Br. J. Urol. (1995) 76:325-336.
22. CAVALLINI G: Alpha-1 blockade pharmacotherapy in primative psychogenic premature ejaculation resistant to psychotherapy. Eur. Urol. (1995) 28:126-130.
23. DEBRUYNE FMJ, VAN DER POEL HG: Clinical experience in europe with uroselective alpha-1-antagonists. Eur. Urol. (1999) 36(Suppl. 1):54-58.
24. LUCAS B, GRANGE JC, MCCARTHY C, COMET D: Clinical uroselectivity: a 3 year follow up in general practice. BPH Group In General Practice. Eur. Urol. (1998) 33(Suppl. 2):28-33.
25. BUZELIN JM, DELAUCHE-CAVALLIER MC, ROTH S GEFFRIAUD-RICOUARD, C, SANTONI JP: Clinical uroselectivity. evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1997) 79:898-906.
26. DEBRUYNE FMJ, JARDIN A, COLLOI D et al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. The European Alfin Study Group. Eur. Urol. (1998) 34:169-175.
27. HOFNER K, JONAS U: Alfuzosin: a clinically uroselective alpha-1-blocker. World J. Urol. (2002) 19:405-412.
28. DE LA ROSETTE J, KORTMANN B, ROSSI C, SONKE G, FLORATOS D, KIEMENEY L: Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J. Urol. (2002) 167:1734-1739.
29. FORRAY C, NOBLE SA: Subtype selective alpha-1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin. Investig. Drugs (1999) 8(12):2073-2094.
30. MARTIN DJ, ANGEL I, ARBILLA S: Functional uroselectivity. Eur. Urol. (1998) 33(Suppl. 2):12-18.
31. ECKERT RE, SCHREIER U, ALLOUSSI S et al.: Zellulare Grundlage der dynamischen, infravesikalen Obstruktion im Rahmen der benignen Prostatahyperplasie: Rolle von Alpharezeptorenblockern und zyklischen Nukleotiden. Akt Urol. (1998) 29:252-260.
32. LOWE FC, DJAVAN R: Prospective randomized trial to evaluate the side effect profile of tamsulosin versus terazosin in 1983 men with benign prostatic hyperplasia. J. Urol. 167(4);267 (Abstract 1032).
33. ROEHRBORN CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology (2001) 58(6A): 55-64.
34. MCKEAGE K, PLOSKER GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs (2000) 62(4):633-65S.
35. WILDE MI, FITTON A, MCTAVISH D: Alfuzosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs (1993) 45(3):410-429.
36. VAN KERREBROECK EV: The efficacy and safety of a new once-a-day formulation of an alpha-blocker. Eur. Urol. (2001) 39(Suppl. 6):19-26.
37. ALLHAT COLLABORATIVE RESEARCH GROUP: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2000) 283:1967-1975.